A panel of 4 genes (MYF6, SIX6, BCL2 and RARB) was able to diagnose stage I NSCLC from non-cancerous lung diseases with a sensitivity of 93.07% and a specificity of 86.67%. Here, SIX6 is linked to lung disorder.